Lam Samuel S K, Zhou Feifan, Hode Tomas, Nordquist Robert E, Alleruzzo Luciano, Raker Joseph, Chen Wei R
Immunophotonics Inc., 4320 Forest Park Ave. #303, St. Louis, MO 63108, USA.
Biophotonics Research Laboratory, Center for Interdisciplinary Biomedical Education and Research, University of Central Oklahoma, Edmond, OK 73034, USA.
Discov Med. 2015 Apr;19(105):293-301.
Since the invention of Coley's toxin by William Coley in early 1900s, the path for cancer immunotherapy has been a convoluted one. Although still not considered standard of care, with the FDA approval of trastuzumab, Provenge and ipilimumab, the medical and scientific community has started to embrace the possibility that immunotherapy could be a new hope for cancer patients with otherwise untreatable metastatic diseases. This review aims to summarize the development of some major strategies in cancer immunotherapy, from the earliest peptide vaccine and transfer of tumor specific antibodies/T cells to the more recent dendritic cell (DC) vaccines, whole cell tumor vaccines, and checkpoint blockade therapy. Discussion of some major milestones and obstacles in the shaping of the field and the future perspectives is included. Photoimmunotherapy is also reviewed as an example of emerging new therapies combining phototherapy and immunotherapy.
自20世纪初威廉·科利发明科利毒素以来，癌症免疫疗法的发展道路一直曲折。尽管仍未被视为标准治疗方法，但随着美国食品药品监督管理局（FDA）批准曲妥珠单抗、普罗文奇和伊匹木单抗，医学界和科学界已开始接受免疫疗法可能为患有其他无法治疗的转移性疾病的癌症患者带来新希望这一可能性。本综述旨在总结癌症免疫疗法中一些主要策略的发展，从最早的肽疫苗以及肿瘤特异性抗体/T细胞的转移，到最近的树突状细胞（DC）疫苗、全细胞肿瘤疫苗和检查点阻断疗法。文中还讨论了该领域形成过程中的一些主要里程碑和障碍以及未来展望。光免疫疗法作为光疗与免疫疗法相结合的新兴新疗法的一个例子也进行了综述。
